ACTRN12610000131055招募中不适用
ABSORB EXTEND A Continuation in the Clinical Evaluation of the Abbott Vascular Everolimus-Eluting BioresorbableVascular Scaffold in the Treatment of Subjects With de Novo NativeCoronary Artery Lesions
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Up to two de novo lesions can be treated, each located in a separate native epicardial vessel.
- •Target lesion(s) must measure <= 28 mm in length by Qualitative Coronary Angiography (QCA), or by visual estimation if on line QCA is not available.
- •Target lesion(s) must be in a major artery or branch with a visually estimated stenosis of >= 50% and < 100% with a Thrombolysis in Myocardial Infarction (TIMI) flow of >= 1.
- •If two treatable lesions meet the inclusion criteria they must be in separate major epicardial vessels.
- •Percutaneous interventions for lesions in a non-target vessel are allowed if done >= 30 days prior to or if planned to be done > 6 months after the index procedure.
- •Percutaneous intervention for lesions in the target vessel are allowed if done > 6 months prior to or if planned to be done 6 months after the index procedure.
排除标准
- •Lesion(s) located within an arterial or saphenous vein graft or distal to a diseased (defined as vessel irregularity per angiogram and > 20% stenosed lesion by visual estimation) arterial or saphenous vein graft.
- •Lesion(s) involving a bifurcation with side branch vessel >= 2 mm in diameter, ostial lesion > 40% stenosed by visual estimation or side branch requiring predilatation.
- •Total occlusion (TIMI flow 0), prior to wire passing.
- •Target vessel(s) contains visible thrombus.
- •Another clinically significant lesion is located in the same epicardial vessel (including side branch) as the target lesion(s).
- •Subject has received brachytherapy in any epicardial vessel (including side branches).
研究者
相似试验
招募中
不适用
Prospective clinical study to confirm and extend the correlation between HSD11B1 polymorphisms, bone mineral density, and cortisol metabolism in patients with osteoporosisType 1 diabetes mellitusM80M81M82E10E11E12E13E14E78F32F33F34Osteoporosis with pathological fractureOsteoporosis without pathological fractureOsteoporosis in diseases classified elsewhereType 2 diabetes mellitusMalnutrition-related diabetes mellitusOther specified diabetes mellitusUnspecified diabetes mellitusDisorders of lipoprotein metabolism and other lipidaemiasDepressive episodeRecurrent depressive disorderPersistent mood [affective] disordersDRKS00016601niversitätsmedizin Göttingen500
已完成
不适用
A Prospective and Consecutive Clinical Evaluation of Soft Tissue Regeneration*s L-C Ligament® in Primary ACL ReconstructioNL-OMON53168Biorez, Inc.15
进行中（未招募）
1 期
ong-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.Dermatitis, AtopicCTIS2023-508474-29-00Glaxosmithkline Research & Development Limited158
进行中（未招募）
1 期
ong-term safety of IbrutinibCLL, SLL, MCL, WM, DLBCL, FL, MZL, multiple myeloma, GvHD, pancreaticcancer, kidney cancer, bladder cancer, stomach cancer, throat cancer,colon cancerMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10041152Term: Small lymphocytic lymphoma, consistent with CLL (Working Formulation)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10043515Term: Throat cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10009944Term: Colon cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10042080Term: StEUCTR2016-004356-30-ITPHARMACYCLICS SWITZERLAND GMBH500
进行中（未招募）
1 期
ong-term safety of IbrutinibMedDRA version: 21.1Level: PTClassification code 10043515Term: Throat cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10009944Term: Colon cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10042080Term: Stomach cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10029473Term: Nodular (follicular) lympEUCTR2016-004356-30-BEPharmacyclics Switzerland GmbH500